We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MPI Research Continues Toxicology Expansion
News

MPI Research Continues Toxicology Expansion

MPI Research Continues Toxicology Expansion
News

MPI Research Continues Toxicology Expansion

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MPI Research Continues Toxicology Expansion"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

As part of a series of planned expansions, MPI Research announced the immediate availability of additional toxicology capacity. Through its portfolio of services the company generates critical safety data for the pharmaceutical and biotechnology industries prior to a new drug candidate’s introduction to humans.

Completed July 20th, the 79,000 square foot toxicology expansion project includes the addition of 84 animal rooms, new surgical suites and accommodations for specialized infusion work.

The project is part of a multi-phased expansion plan fueled by the growing research and development needs of the pharmaceutical and biotechnology industries. In 2006, the company completed toxicology expansion projects totaling $65 million, including 95 animal rooms plus significant laboratory and office space.

“Our expansion projects are driven by our customers’ need for timely, cost effective research and development services,” said Bill Parfet, Chairman and Chief Executive Officer of MPI Research. “Our ongoing investments in capacity, service expansions and infrastructure will further assure our customers of timely study starts, quality services, and on-time reporting to keep their drug development programs moving forward.”

Advertisement